Biotech Today: From Sustainable Biomaterials to First-in-Class Therapies

May 28, 2025

DENVER, Colo., May 28, 2025 (247marketnews.com)- From sustainable biomaterials to first-in-class therapies, here’s how today’s leaders— Kraig Biocraft Laboratories, Aspire Biopharma, Spero Therapeutics, GSK, and Veru—are pushing the frontiers of science and shareholder value.

Kraig Biocraft Laboratories: Exclusive Leader in Spider Silk Enters Next Phase of Commercial Scale

Kraig Biocraft Laboratories (OTCQB:KBLB) revealed a major leap forward in its commercial expansion strategy, with the successful development of a new recombinant spider silk parental line, purpose-built for large-scale commercial production.

Kraig is currently the only company in the world with a functional and scalable platform for spider silk mass production. This puts KBLB in a first-mover position in a sector projected to grow into a $42–$50 billion global market by the end of the decade.

“As we prepare to implement double hybrid crosses into our production platform, we are opening the door to greater scalability, efficiency, and product consistency,” said founder and CEO Kim Thompson. “This is a key step forward in our mission to bring the power of spider silk to mainstream markets.”

Why it matters:
Spider silk is one of the strongest, lightest, and most versatile fibers on Earth—stronger than steel by weight and biodegradable. Its applications range from performance apparel and composites to biomedical devices, aerospace, and national defense. As companies and governments alike look for advanced, eco-friendly materials, Kraig’s scalable platform gives it a competitive edge that could be nearly impossible to replicate in the near term.

Aspire Biopharma (NASDAQ:ASBP): First Patient Dosed in Fast-Acting Aspirin Phase 1 Trial

Aspire Biopharma began dosing in its U.S.-based Phase 1 crossover study for a high-dose, fast-acting sublingual aspirin formulation. This clinical trial compares the PK/PD profile of its powdered and granule formulations to standard oral aspirin in healthy volunteers.

Topline results are expected in early Q3, and successful outcomes could pave the way for accelerated FDA approval.

Why it matters:
Aspire’s innovation could redefine first-line emergency care in stroke and heart attack, where speed of drug delivery can mean the difference between life and death.

Spero Therapeutics (NASDAQ:SPRO) and GSK (NYSE:GSK): Oral Carbapenem Hits Phase 3 Home Run

Spero and GSK announced that the PIVOT-PO Phase 3 trial for tebipenem HBr, an oral antibiotic for complicated urinary tract infections (cUTIs), was stopped early after meeting its efficacy endpoint. The trial showed that oral tebipenem was non-inferior to IV imipenem, opening the door for a more accessible treatment pathway.

FDA filing is planned for the second half of 2025.

Why it matters:
Tebipenem HBr could become the first oral carbapenem approved in the U.S., disrupting a space where hospitalizations and IV-only regimens dominate.

Veru (NASDAQ:VERU): Focus Tightens on AR+ Breast Cancer Trials

Veru continued its pivot toward oncology with updates on enobosarm, its androgen receptor modulator for AR+ triple-negative breast cancer. This high-need area represents a precision medicine frontier with limited current options.

Why it matters:
Veru is repositioning after prior setbacks with a sharp focus on orally administered, targeted oncology therapies, especially for difficult-to-treat patient populations.

Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.

Please go to https://247marketnews.com/kblb-disclosure/ for disclaimer information.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (KBLB, ASBP, SPRO, GSK, VERU)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.